These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 6494246)

  • 1. Phase IV research by pharmaceutical companies.
    Hakkarainen H; Hattab JR; Venulet J
    Pharmacopsychiatry; 1984 Sep; 17(5):168-75. PubMed ID: 6494246
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Developing methodologies for monitoring long-term safety of psychotropic medications in children: report on the NIMH conference, September 25, 2000.
    Greenhill LL; Vitiello B; Abikoff H; Levine J; March JS; Riddle MA; Capasso L; Cooper TB; Davies M; Fisher P; Findling RL; Fried J; Labellarte MJ; McCracken JT; McMahon D; Robinson J; Skrobala A; Scahill L; Varipatis E; Walkup JT; Zito JM
    J Am Acad Child Adolesc Psychiatry; 2003 Jun; 42(6):651-5. PubMed ID: 12921472
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How to anticipate the assessment of the public health benefit of new medicines?
    Massol J; Puech A; Boissel JP;
    Therapie; 2007; 62(5):427-35. PubMed ID: 18206104
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Our policy and future tasks related to ICH in anti-cancer drug development--a discussion from the viewpoint of an enterprise].
    Ekimoto H
    Gan To Kagaku Ryoho; 1997 Jan; 24(2):229-37. PubMed ID: 9030236
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anticancer Drug Development: The Way Forward.
    Connors T
    Oncologist; 1996; 1(3):180-181. PubMed ID: 10387985
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
    Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
    Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phased approach to clinical testing: criteria for progressing from Phase I to Phase II to Phase III studies.
    André FE; Foulkes MA
    Dev Biol Stand; 1998; 95():57-60. PubMed ID: 9855414
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evidence used for approval of new drugs.
    Botstein P
    Isr J Med Sci; 1986; 22(3-4):197-200. PubMed ID: 3528042
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A cross-sectional evidence-based review of pharmaceutical promotional marketing brochures and their underlying studies: is what they tell us important and true?
    Cardarelli R; Licciardone JC; Taylor LG
    BMC Fam Pract; 2006 Mar; 7():13. PubMed ID: 16515686
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A European pharmaceutical company initiative challenging the regulatory requirement for acute toxicity studies in pharmaceutical drug development.
    Robinson S; Delongeas JL; Donald E; Dreher D; Festag M; Kervyn S; Lampo A; Nahas K; Nogues V; Ockert D; Quinn K; Old S; Pickersgill N; Somers K; Stark C; Stei P; Waterson L; Chapman K
    Regul Toxicol Pharmacol; 2008 Apr; 50(3):345-52. PubMed ID: 18295384
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The EU paediatric regulation: effects on paediatric psychopharmacology in Europe.
    Stoyanova-Beninska VV; Wohlfarth T; Isaac M; Kalverdijk LJ; van den Berg H; Gispen-de Wied C
    Eur Neuropsychopharmacol; 2011 Aug; 21(8):565-70. PubMed ID: 20621456
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Contraceptive development and clinical trials.
    Fraser IS
    Clin Reprod Fertil; 1986 Feb; 4(1):75-85. PubMed ID: 3708511
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pediatric clinical trial experience: government, child, parent and physician's perspective.
    Salazar JC
    Pediatr Infect Dis J; 2003 Dec; 22(12):1124-7. PubMed ID: 14688585
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alternative strategies in drug development: clinical pharmacological aspects.
    Kuhlmann J
    Int J Clin Pharmacol Ther; 1999 Dec; 37(12):575-83. PubMed ID: 10599949
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug safety in psychiatry--an objective for drug monitoring in phase IV.
    Schmidt LG; Müller-Oerlinghausen B
    Pharmacopsychiatry; 1984 Sep; 17(5):152-6. PubMed ID: 6494244
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The private practice study group as phase-IV research tool.
    Helmchen H; Linden M; Schüssler G
    Pharmacopsychiatry; 1984 Sep; 17(5):157-61. PubMed ID: 6494245
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Off-label use of psychotropic medications in pediatric wards: a prospective study].
    Winterfeld U; Le Heuzey MF; Acquaviva E; Mouren MC; Brion F; Bourdon O
    Arch Pediatr; 2009 Sep; 16(9):1252-60. PubMed ID: 19640689
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Postmarketing surveillance.
    Oleen MA
    Can J Hosp Pharm; 1987 Oct; 40(5):171-2, 179-80. PubMed ID: 10284449
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.